Shots:

• The US FDA has approved fexinidazole (PO- qd- 10days treatment) for both stages of Trypanosoma brucei gambiense form of sleeping sickness in patients aged >6yrs. & weighing at least 20 kg. The therapy has developed under the collaboration with DNDi- DRC- CAR & Sanofi
• Sanofi & partners are committed to access fexinidazole in all endemic countries for sleeping sickness because current treatment options for sleeping sickness are effective but troublesome for patients & health workers who live in remote areas
• Following the approval- Tropical disease PRV has been awarded to DNDi. Sanofi is committed to provide drug free-of-charge to WHO for distribution affected countries

  Ref: Sanofi | Image: Medcity News